You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
普萊柯(603566.SH)獲新獸藥註冊證書
格隆匯 05-15 15:42

格隆匯5月15日丨普萊柯(603566.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准公司和子公司洛陽惠中生物技術有限公司(以下簡稱“惠中生物”)申報的“雞新城疫、禽流感(H9亞型)二聯滅活疫苗(N7a株+SZ株)”為新獸藥,農業農村部於2020年5月14日公示了核發《新獸藥註冊證書》(農業農村部公告第297號)事項。

雞新城疫、禽流感(H9亞型)二聯滅活疫苗(N7a株+SZ株)中含有滅活的雞新城疫病毒N7a株、滅活的禽流感(H9亞型)病毒SZ株。用於預防雞新城疫和H9亞型禽流感。免後21日可產生免疫力,免疫期為6個月。

雞新城疫、H9亞型禽流感是嚴重危害我國及世界養禽業的重要疫病,具有流行範圍廣、發病率高、混合感染情況下死亡率高等特點,給養禽業造成了巨大的經濟損失。公司開發的雞新城疫、禽流感(H9亞型)二聯滅活疫苗(N7a株+SZ株)產品具有以下優勢:(1)利用反向遺傳學技術對臨牀分離的雞新城疫病毒基因VII型PLK-N-06株強毒株進行致弱所獲得的弱毒株N7a株,保留了強毒株良好的免疫原性,製備的疫苗可顯著降低免疫雞隻強毒感染後的載毒量和排毒率;(2)通過交叉免疫保護試驗篩選的禽流感(H9亞型)毒株SZ株,抗原譜廣,對流行毒株交叉保護性好;(3)通過抗原濃縮與新型佐劑技術,實現免疫劑量低至0.15~0.3ml,在保證免疫效果的同時降低免疫劑量、減少雞體疫苗殘留。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account